The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 30, 2025

Filed:

Dec. 23, 2024
Applicants:

Olema Pharmaceuticals, Inc., San Francisco, CA (US);

Aurigene Oncology Limited, Karnataka, IN;

Inventors:

Brian R. Hearn, Moraga, CA (US);

David C. Myles, Berkeley, CA (US);

Reena Chawla, San Francisco, CA (US);

David Yeghikyan, Fremont, CA (US);

Chandregowda Venkateshappa, Bangalore, IN;

Susanta Samajdar, Bangalore, IN;

Kalisankar Bera, Bangalore, IN;

Suraj Tatyasaheb Gore, Maharashtra, IN;

Raymond A. Ng, Pleasant Hill, CA (US);

Assignees:

Olema Pharmaceuticals, Inc., San Francisco, CA (US);

Aurigene Oncology Limited, Karnataka, IN;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 231/12 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/426 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61P 35/00 (2006.01); C07D 239/34 (2006.01); C07D 277/34 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 231/12 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/426 (2013.01); A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61P 35/00 (2018.01); C07D 239/34 (2013.01); C07D 277/34 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01);
Abstract

The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.


Find Patent Forward Citations

Loading…